Related Experiment Video

Updated: Oct 5, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

565

Addressing screams for evidence on renoprotection by GLP-1 receptor agonists

Takayoshi Sasako1, Toshimasa Yamauchi1

  • 1Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kidney International
|January 23, 2022
PubMed

Insights

Glucagon-like peptide-1 receptor agonists demonstrated renoprotective effects, reducing renal outcomes compared to dipeptidyl peptidase-4 inhibitors. This study offers hope for future clinical trials investigating these kidney benefits.

Area of Science:

  • Nephrology
  • Endocrinology
  • Clinical Pharmacology

Background:

  • Growing evidence suggests benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
  • Renoprotective effects of GLP-1 RAs require further confirmation in clinical trials.
  • Comparison with dipeptidyl peptidase-4 inhibitors (DPP-4i) is crucial for understanding differential renal benefits.

Purpose of the Study:

  • To evaluate the renoprotective effects of GLP-1 RAs compared to DPP-4i.
  • To assess the impact of GLP-1 RAs on renal outcomes in a real-world cohort.
  • To provide evidence supporting the use of GLP-1 RAs for kidney protection.

Main Methods:

  • Retrospective cohort study utilizing data from the Stockholm Creatinine Measurements project.
  • Analysis of renal outcomes in patients treated with GLP-1 RAs versus DPP-4i.
  • Statistical methods to compare renal event rates between the two drug classes.

Main Results:

  • GLP-1 RAs were associated with a reduced risk of renal outcomes compared to DPP-4i.
  • The study identified a significant renoprotective effect of GLP-1 RAs.
  • Findings were observed in a large cohort from Stockholm, Sweden.

Conclusions:

  • GLP-1 RAs exhibit significant renoprotective properties.
  • These findings support the use of GLP-1 RAs for preventing kidney disease progression.
  • Further prospective clinical trials are warranted to solidify these renoprotective claims.

More Related Videos

Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation07:44

Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation

Published on: August 7, 2015

16.4K
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.7K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
461
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
290
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
306
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K